PERSPEKTIVY ANTI-V-KLETOChNOY TERAPII SISTEMNOY KRASNOY VOLChANKI


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Despite the existing arsenal of glucocorticoids and cytotoxic drugs, systemic lupus erythematosus (SLE) is a disease with high mortality, significant organ damage and poor quality of life. Appeared genetically engineered biological agents for blocking the function of B lymphocytes give new prospects in the management of patients with SLE: relief of life-threatening situation (rituximab), reduction of the development of side effects of conventional therapy (belimumab and epratuzumab). These drugs can improve the quality of life of patients with SLE.

Full Text

Restricted Access

References

  1. Arbuckle M.R., McClain M.T., Rubertone M.V., et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N. Engl. J. Med. 2003;349:1526-33.
  2. James J.A., Harley J.B., Scofield R.H. Epstein-Barr virus and systemic lupus erythematosus. Curr. Opin. Rheumatol. 2006;18:462-67.
  3. Costenbader K.H., Gay S., Alarcon-Riquelme M.E., laccarino L., Doria A. Genes, epigenetic regulation and environmental factors: which is the most relevant in developing autoimmune diseases? Autoimmun. Rev. 2012;11:604-09.
  4. Bertoli A.M., Alarcon G.S. Epidemiology of Systemic Lupus Erythematosus, in: G.C. Tsokos, C. Gordon, J.S. Smolen (Eds.), Systemic Lupus Erythematosus, Elsevier Inc., Philadelphia, 2007. P. 1-18.
  5. Pons-Estel G.J., Alarcon G.S., Scofield L., Reinlib L., Cooper G.S. Understanding the epidemiology and progression of systemic lupus erythematosus. Semin. Arthritis Rheum. 2010;39:257-68.
  6. Danchenko N., Satia J.A., Anthony M.S. Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden. Lupus. 2006;15(5):308-18.
  7. Martin F., Chan A.C. B cell immunobiology in disease: evolving concepts from the patients. Rheumatology (Oxford). 2005;44(12): 1542-45.
  8. Carnahan J., Wang P., Kendall R., et al. Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties. Clin. Cancer Res. 2003;9(10 Pt 2): 3982-90.
  9. Carnahan J., Stein R., Qu Z., et al. Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab. Mol. Immunol. 2007;44(6):1331-41.
  10. Ding C., Jones G. Belimumab Human Genome Sciences/Cambridge Antibody Technology/ GlaxoSmithKline. Curr. Opin. Investig Drugs. 2006;7(5):464-72.
  11. Dall'Era M., Chakravarty E., Wallace D., et al. Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter,phase Ib, double-blind, placebo-controlled, dose-escalating trial. Arthritis Rheum. 2007;56:4142-50.
  12. Merrill J.T., Burgos-Vargas R., Westhovens R., et al. The efficacy and safety of abatacept in patients with non-lifethreatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase lib, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2010;62:3077-87.
  13. Cardiel M.H., Tumlin J.A., Furie R.A., et al. Abetimus sodium for renal flare in systemic lupus erythematosus: results of a randomized, controlled phase lll trial. Arthritis Rheum. 2008;8:2470-80.
  14. Perosa F.E., Favoino M.A., Caragnano M.P., Dammacco F. CD20: a target antigen for immunotherapy of autoimmune diseases. Autoimmunity Rev. 2005;4(8):526-31.
  15. Leandro M.J., Edwards J.C., Cambridge G., et al. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum. 2002;46:2673-77.
  16. Wallace D.J. Advances in drug therapy for systemic lupus erythematosus, BMC Med. 2010;29:77.
  17. Jordan N., Lutalo P.M.K., D'Cruz D.P. Novel therapeutic agents in clinical development for systemic lupus erythematosus. BMC Medicine. 2013;11:120.
  18. Furtado J., Isenberg D.A. B cell elimination in systemic lupus erythematosus. Clinical immunology. 2013;146:90-103.
  19. Catapano F., Chaudhry A.N., Jones R.B., et al. Long-term efficacy and safety of rituximab in refractory and relapsing systemic lupus erythematosus. Nephrol. Dial Transplant. 2010; 25:3586-92.
  20. Vital E.M., Dass S., Buch M.H., et al. B cell biomarkers of rituximab responses in systemic lupus erythematosus, Arthritis Rheum. 2011 ;63:3038-47.
  21. Соловьев С.К., Торгашина А.В., Насонов Е.Л., Александрова Е.Н. Эффективность ритуксимаба у больных системной красной волчанкой. Собственные результаты. Научно-практическая ревматология. 2010;4:52-6.
  22. Левицки А., Линден С., ван Волленховен Р.Ф. Ритуксимаб в терапии системной красной волчанки. Научно-практическая ревматология. 2013;3:223-31.
  23. van Vollenhoven R.F., Gunnarsson l., Welin-Henriksson E., et al. Biopsy-verified response of severe lupus nephritis to treatment with rituximab (anti-CD20 monoclonal antibody) plus cyclophosphamide after biopsy-documented failure to respond to cyclophosphamide alone. Scand. J. Rheumatol. 2004;33:423-27.
  24. Gunnarsson l., Jonsdottir T. Rituximab treatment in lupus nephritis - where do we stand? Lupus. 2013;22:381-89.
  25. Melander C., Sallee M., Trolliet P., et al. Rituximab in severe lupus nephritis: Early B-cell depletion affects long-term renal outcome. Clin. J. Am. Soc. Nephrol. 2009;4:579-87.
  26. Li E.K., Tam L.S., Zhu T.Y., et al. is combination rituximab with cyclophosphamide better than rituximab alone in the treatment of lupus nephritis? Rheumatology (Oxford). 2009;48:892-98.
  27. Gunnarsson l., Sundelin B., Jonsdottir T., et al. Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis. Arthritis Rheum. 2007;56:1263- 72.
  28. Торгашина А.В., Соловьев С.К., Александрова Е.Н. и др. Применение ритуксимаба у больных волчаночным нефритом. Научнопрактическая ревматология. 2010;4:14-26.
  29. Diaz-Lagares C., Croca S., Sangle S., et al. Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: Pooled data from European cohorts. Autoimmun Rev. 2012;11:357-64.
  30. Furie R., Rovin R., Latnis K.M., et al. Efficacy and safety of rituximab in subjects with active proliferative lupus nephritis (LN): results from the randomized, double-blind phase ill LUNAR study. Arthritis Rheum. 2009;60:429.
  31. Merrill J.T., Neuwelt C.M., Wallace D.J., et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase ll/ill systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 2010;62:222-33.
  32. Terrier B., Amoura Z., Ravaud P., et al. Safety and Efficacy of Rituximab in Systemic Lupus Erythematosus. Arthritis Rheum. 2010; 62:2458-66.
  33. Witt M., Grunke M., Proft F., et al. Clinical outcomes and safety of rituximab treatment for patients with systemic lupus erythematosus (SLE) -results from a nationwide cohort in Germany (GRAlD). Lupus. 2013;22:1142-49.
  34. Condon M.B., Ashby D., Pepper R.J., et al. Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. Ann. Rheum. Dis. 2013;72:1280-86. doi: 10.1136/annrheumdis-2012-202844.
  35. Traczewski P., Rudnicka L. Treatment of systemic lupus erythematosus with epratuzumab. Br. J. Clin. Pharmacol. 2011;71:175-82.
  36. Jacobi A.M., Goldenberg D.M., Hiepe F., et al. Differential effects of epratuzumab on peripheral blood B cells of patients with systemic lupus erythematosus versus normal controls. Ann. Rheum. Dis. 2008;67:450-57.
  37. Wallace D.J., Gordon C., Strand V., et al. Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, doubleblind, placebo-controlled, multicentre studies (ALLEVlATE) and follow-up. Rheumatology (Oxford). 2013;52(7):1313-22. doi: 10.1093/ rheumatology/ket129. Epub 2013 Mar 28.
  38. Dorner T., Kaufmann J., Wegener W.A., et al. lnitial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus Arthritis Res. Ther. 2006;8(3):R74.
  39. Carnahan J., Stein R., Qu Z., et al. Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab. Mol. lmmunol. 2007;44(6):1331-41.
  40. FDA approves Benlysta to treat lupus. [Last accessed on 2011 Mar 28]. Available from:http:// www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/ucm246489.htm.
  41. Lied G.A., Berstad A. Functional and clinical aspects of the B cell-activation factor (BAFF): a narrative review. Scand. J. lmmunol. 2011;73:1-7.
  42. Stohl W., Metyas S., Tan S.M., et al. B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: Longitudinal observations. Arthr Rheum. 2003;48:3475-86.
  43. Petri M., Stohl W., Chatham W., et al. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Arthr Rheum. 2008;58:2453-59.
  44. Baker K.P., Edwards B.M., Main S.H., et al. Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthr Rheum 2003;48:3253-65.
  45. Navarra S.V., Guzman R.M., Gallacher A.E., et al. BLlSS-52 Study Group.Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: A randomised, placebo-controlled, phase 3 trial. Lancet. 2011;3 77:721-31.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2014 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies